SCHEMBL6085628

SCHEMBL6085628

Cc1ccc2nc(-c3c[nH]nc3-c3ccc(NC(=O)C4(c5ccccc5)CC4)cc3)oc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
HTT P42858 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
CETP P11597 2/20 0.51
MAPT P10636 7/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
POLB P06746 1/20 0.49
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
AGPAT2 O15120 1/20 0.44
TP53 P04637 3/20 0.44
BAZ1A Q9NRL2 1/20 0.43
CEPT1 Q9Y6K0 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087573 0.92 MAPT (0.51) KDM4EHTTTDP1CETPMAPT
SCHEMBL6086086 0.88 MAPT (0.50) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6086480 0.85 MAPT (0.48) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6084464 0.85 MAPT (0.47) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6084212 0.84 CEPT1 (0.51) KDM4EHTTTDP1MAPTSMN1; SMN2
SCHEMBL6084581 0.81 MAPT (0.54) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6085303 0.81 MAPT (0.50) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6086313 0.81 CETP (0.56) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6085906 0.80 MAPT (0.53) KDM4ECETPMAPTSMN1; SMN2POLB
SCHEMBL6085844 0.79 CEPT1 (0.49) KDM4EHTTTDP1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 KDM4E 1175/4885HTT 2133/4885TDP1 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.